Xeris Biopharma (NASDAQ:XERS) said that the U.S. Patent and Trademark Office issued a patent covering its XeriSol formulations.
The Patent Number 11,590,205 is titled 'Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents.'
The claims in the patent cover certain pharmaceutical formulations in Xeris' Gvoke product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations.
"The addition of this new patent further strengthens our intellectual property position in the XeriSol™ platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products," said Xeris' Chairman and CEO Paul Edick.